Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Many patients in intensive care (ICU) need help to breathe on a breathing machine and need
pain killers and sedatives to keep them comfortable and pain free. However, keeping patients
too deeply sedated can make their ICU stay longer, can cause ICU confusion (delirium) and
afterwards may cause distressing memories. Ideally patients should be kept less sedated, but
it is difficult to get the balance of sedation and comfort right.
The investigators want to know whether starting an alpha2-agonist drug early in ICU can help
keep patients more lightly sedated but still comfortable, and whether patients spend less
time on the ventilator. The investigators also want to know how safe they are and if they can
improve important outcomes during ICU stay and during recovery. The investigators also want
to know if they are value for money.
Phase:
Phase 3
Details
Lead Sponsor:
University of Edinburgh
Collaborators:
Edinburgh Napier University Imperial College London King's College London NHS Lothian Queen's University, Belfast Royal Surrey County Hospital NHS Foundation Trust The University of Queensland University College, London University Hospital of Wales University of Cambridge University of Manchester University of Warwick West Hertfordshire Hospitals NHS Trust